The number of immunotherapies in clinical trial rolls over 5000 now, and immunology has become a common approach in some cancers. Cell technologies, as a growing sub-field in the immunotherapy landscape, have progressed considerably and now represent a $26 billion financial opportunity by 2030, according to a report by Roots …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.